Welcome to our dedicated page for Elevance Health news (Ticker: ELV), a resource for investors and traders seeking the latest updates and insights on Elevance Health stock.
Elevance Health, Inc. (NYSE: ELV) generates a steady stream of news as a major participant in the direct health and medical insurance carriers industry. Company updates frequently focus on financial performance, member experience initiatives, digital tools, and community health programs. Investors and observers following ELV news can see how Elevance Health communicates its strategy as a lifetime, trusted health partner serving over 109 million consumers through medical, pharmacy, behavioral, clinical, home health, and complex care solutions.
News coverage often includes earnings results and guidance, such as quarterly financial releases that detail segment performance for Health Benefits and Carelon, membership trends across commercial, Medicare, Medicaid, and Federal Employee Program lines, and commentary on benefit expense ratios and operating metrics. The company also issues announcements about upcoming conference calls and webcasts where management reviews results and outlook with investors.
Another key theme in Elevance Health news is the evolution of the healthcare consumer experience. Articles describe AI-enabled digital solutions, including the Virtual Assistant available through the Sydney Health app, which helps members understand benefits, compare costs, and find in-network providers. The company also highlights care management programs, concierge-style support for serious illnesses, and models such as “My Health Advocate” in affiliated Medicare plans.
Elevance Health news frequently covers whole-health and community initiatives. Examples include Food as Medicine partnerships with the National Association of Community Health Centers, school-based fitness facility upgrades, and expanded access to doula care and social supports in certain Medicare Advantage and Medicaid plans. Governance developments, such as the appointment of independent directors to the board and related committee assignments, are also reported through press releases and SEC-linked announcements.
By reviewing the ELV news feed on this page, readers can follow financial disclosures, strategic initiatives, digital and clinical innovations, and community-focused programs that shape Elevance Health’s role in the health benefits and healthcare services landscape.
Elevance Health (NYSE: ELV) reported strong Q1 2025 financial results with operating revenue reaching $48.8 billion, up 15.4% year-over-year. The company achieved an adjusted operating gain of $3.3 billion, representing a 4.1% increase from Q1 2024.
Key financial metrics include diluted EPS of $9.61 and adjusted diluted EPS of $11.97. The company reaffirmed its FY 2025 adjusted diluted EPS guidance of $34.15 to $34.85. During Q1, Elevance returned $1.3 billion to shareholders through share repurchases ($880 million) and dividends ($386 million).
The Health Benefits segment generated $41.4 billion in operating revenue, while Carelon's revenue grew 38% to $16.7 billion. Medical membership increased by 99,000 from year-end 2024, reaching approximately 45.8 million members. The company declared a Q2 2025 dividend of $1.71 per share, payable on June 25, 2025.
Elevance Health (NYSE: ELV) has announced it will release its first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. EDT. The company will host a conference call at 8:30 a.m. EDT the same day to discuss the results and outlook.
Participants can access the call using the following numbers:
- Domestic: 888-947-9963 (Access Code: 3972058)
- International: 312-470-0178 (Access Code: 3972058)
A replay will be available from 11:30 a.m. EDT on April 22 until May 22, 2025, through:
- Domestic: 800-396-1242
- International: 203-369-3272
Elevance Health (NYSE: ELV) reported Q4 2024 operating revenue of $45.0 billion, up 6% year-over-year, and full-year 2024 revenue of $175.2 billion, a 3% increase. The company's Q4 2024 adjusted diluted EPS was $3.84, while full-year adjusted EPS reached $33.04.
The benefit expense ratio increased to 92.4% in Q4, up 320 basis points from the previous year, primarily due to higher Medicaid medical cost trends. The company's operating cash flow was $5.8 billion in 2024. During Q4, Elevance repurchased 4.5 million shares for $1.8 billion and increased its quarterly dividend by 5% to $1.71 per share.
Medical membership decreased by 1.1 million to 45.7 million members, mainly due to Medicaid business attrition. Looking ahead, Elevance projects FY 2025 adjusted EPS to be between $34.15 and $34.85.
Mark Farrah Associates (MFA) analyzed Elevance Health's acquisition of Indiana University Health Plans, completed on December 31, 2024. The analysis reveals that Elevance Health, through its Anthem Blue Cross and Blue Shield subsidiary, is the second-largest health insurer in the US with nearly 3.2 million members in Indiana, four times larger than UnitedHealth Group.
In Indiana's Medicare Advantage (MA) market, Elevance ranks third with 134,006 members. The acquisition of IU Health Plans (ranked fifth) strengthens Elevance's position and puts pressure on second-place Humana. MFA's analysis shows Elevance leads MA market share in Indiana's perimeter counties, while IU Health Plans' presence is concentrated in central regions where UnitedHealth dominates.
Elevance Health (NYSE: ELV) has scheduled its fourth quarter and full year 2024 financial results announcement for January 23, 2025, at 6:00 a.m. EST. The company will host a conference call at 8:30 a.m. EST the same day to discuss the results and future outlook.
Participants can join the call using domestic (888-947-9963) or international (312-470-0178) numbers with access code 3972058. A replay will be available from 11:30 a.m. EST on January 23 until February 21, 2025. The event will also be accessible via live webcast on the company's website under the 'Investors' section.
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and various credit ratings for Elevance Health Inc. (NYSE: ELV) and its subsidiaries. The outlook for all ratings remains stable. The affirmations reflect Anthem Health's very strong balance sheet, strong operating performance, and favorable business profile.
Key highlights include a 5-year compound annual capital growth rate of 8%, outpacing premium growth of 6.8%. The company maintains a conservative investment portfolio and sound liquidity with access to $4 billion in credit facilities. Financial leverage increased to 42% due to recent debt issuance but is expected to return to the 40% range by 2025.
Despite challenges in Medicaid membership due to state redeterminations, Elevance maintains strong profitability ratios and operates BCBS plans in 14 states with significant market presence.
Elevance Health (NYSE: ELV) has announced its senior management will present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California. The presentation is scheduled for November 12 at 7:15 a.m. PST (10:15 a.m. EST). A live webcast will be available on the company's website, with a replay accessible for 90 days following the presentation. Interested parties are advised to visit www.elevancehealth.com at least 15 minutes before the presentation to install necessary audio software.
Elevance Health (NYSE: ELV) has appointed Nathan Rich as Vice President of Investor Relations, effective November 11, 2024. Rich will lead the company's investor relations efforts and join the executive leadership team, reporting to CFO Mark Kaye. He succeeds Stephen Tanal, who transitions to CFO of Elevance Health's Government Health Benefits business. Rich brings nearly two decades of experience, previously serving as VP in Global Investment Research at Goldman Sachs and as a sell-side research analyst at Citi.
Adam Herbst has joined Sheppard Mullin as a healthcare partner in New York, becoming the ninth healthcare partner to join in 2024. Previously serving as New York State Department of Health's Deputy Commissioner for Aging and Long Term Care, Herbst brings expertise in healthcare policy, Medicaid reform, and corporate governance. His experience includes overseeing regulation for New York's acute care, post-acute care, disability, and long-term care industries. The firm highlights its active long-term care practice, citing recent major transactions including a strategic partnership with Elevance Health and various joint ventures in the healthcare sector.
Elevance Health (NYSE: ELV) reported third quarter 2024 results with operating revenue of $44.7 billion, a $2.2 billion increase from the prior year. The company's adjusted operating gain was $2.4 billion, with diluted EPS of $4.36 and adjusted diluted EPS of $8.37. Elevance Health revised its 2024 outlook, now expecting GAAP net income per diluted share to be approximately $26.50 and adjusted net income per diluted share to be approximately $33.00.
The benefit expense ratio increased to 89.5%, up 270 basis points, primarily due to a timing mismatch between Medicaid rates and higher member acuity. The operating expense ratio improved to 11.8%, or 9.6% excluding adjustment items. The company's Health Benefits segment saw operating revenue increase to $38.3 billion, while Carelon's operating revenue grew to $13.8 billion. Elevance Health declared a fourth quarter 2024 dividend of $1.63 per share.